Enhanced Detection of Atypical Hyperplasia in Endometrial Polyps by PTEN Expression

Applied Immunohistochemistry and Molecular Morphology

Volumn 12, Issue 1, 2004, Pages 36-39

  Hecht, Jonathan L ^a   Pinkus, Jack L ^b   Pinkus, Geraldine S ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endometrium; Hyperplasia; Polyp; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS DISEASE;

EID: 1542724875     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200403000-00007     Document Type: Article

References (14)

1. Pettersson B, Adami HO, Lindgren A, et al. Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma: a case-control study of curettage specimens. Acta Obstet Gynecol Scand. 1985;64:653-9.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56:403-12.
3. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012-9.
4. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol. 2002;55:326-31.
5. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000;76:287-90.
6. Anastasiadis PG, Koutlaki NG, Skaphida PG, et al. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21:180-3.
7. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4:3005-10.
8. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-40.
9. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126-31.
10. Tabata T, Yamawaki T, Yabana T, et al. Natural history of endometrial hyperplasia: study of 77 patients. Arch Gynecol Obstet. 2001;265:85-8.
11. Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol. 2000;190:462-9.
12. Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58:2500-3.
13. Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115:32-8.
14. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-30.